Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Praulent

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

- PMLiVE

CHMP recommends Gilead’s sofosbuvir for hep C

Set to be first interferon-free treatment regime

Sanofi reception

Sanofi moves closer to arthritis drug filing

Reports positive late-stage results for sarilumab

Sanofi reception

Sanofi pulls development of blood cancer drug

Fedratinib linked to brain disorder during clinical trials

- PMLiVE

New US guidelines to boost statin use but Crestor may miss out

American Heart Association and American College of Cardiology put emphasis on patient characteristics

Novartis building

Novartis offloads diagnostics unit to Grifols for $1.7bn

Part of strategy to focus on more profitable businesses

Bristol-Myers Squibb (BMS) building

BMS exits hep C, diabetes and neuroscience drug discovery

Will discontinue 'broad-based discovery work' in the therapy areas

- PMLiVE

Novartis debates future of Horsham site

UK research centre could close

- PMLiVE

Merck stakes a claim to all-oral hepatitis C market

Positive data for interferon-free regimen

Novartis building

Novartis weighs in on biosimilar naming debate

Files petition urging FDA to keep system where biosimilars share a name with the original drug

Sanofi reception

Sanofi returns to growth in Q3

Diabetes products and Genzyme help company overcome patent cliff

- PMLiVE

Incivek decline forces Vertex job cuts

370 positions to be axed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links